The Effect of Vegetarian Diet on Patients With Metabolic Associated Fatty Liver Disease

The Effect of Vegetarian Diet on Patients With Metabolic Associated Fatty Liver Disease:A Randomized Clinical Trial

In this study, 18-60 years old patients with metabolic associated fatty liver disease(MAFLD) will be recruited to test the intervention effect of vegetarian diet. This randomized clinical trial randomized individuals to a healthy vegetarian diet or a healthy omnivorous diet for 24 weeks. At the baseline and after the 24week intervention, the clinical manifestations of MAFLD, obesity levels, indices for glucose and lipid metabolism parameters, results of questionnaire and fecal samples will be collected and analyzed.

Study Overview

Detailed Description

Dietary control remains an important way for nutritional intervention of metabolic related fatty liver disease. However, studies shows that patients have low compliance to the traditional diet. The topic proposed based on previous studies,recruiting of 220 obesity patients with metabolic associated fatty liver disease aged 18-60. After the informed consent, they will be randomly divided into intervention group and control group, intervention group will be given healthy vegetarian diet intervention and the control group given healthy omnivorous diet. Both diets are in line with the principles of fatty liver treatment. Interventions consisted primarily of face-to -face interview monthly and online interview every 2 weeks, which will be performed by professional dietitians. All participants were asked not to alter their exercise patterns during the study period. The primary outcome was the weight of fat mass after 24 weeks intervention. Secondary outcomes included imaging findings (B-ultrasonic examination and Fibroscan) of MAFLD, liver function, anthropometric measures, plasma lipid and glucose levels. At the meantime, serum oxidative stress indices, results of compliance survey and metabolites of Intestinal flora will be collected and analyzed. Through the above detection of the indicators related to MAFLD and obesity, it is explored whether the vegetarian diet can be an efficient and feasible way to the nutritional therapy of MAFLD.

Study Type

Interventional

Enrollment (Estimated)

220

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Xiuhua Shen, Professor
  • Phone Number: +86-139-1691-0428
  • Email: srachel@126.com

Study Contact Backup

Study Locations

    • Shanghai
      • Shanghai, Shanghai, China, 200092
        • Recruiting
        • Department of Clinical Nutrition, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Clinically diagnosed as fatty liver, and BMI≥24.0kg/m²;
  2. 18-60 years old;
  3. Have not received drug treatment if having hyperglycemia, hyperlipidemia and high uric acid ;
  4. No antibiotics in the last 1 month;
  5. The guardian's informed consent;

Exclusion Criteria:

  1. Have received drug treatment of fatty liver disease within three months;
  2. Patients with with liver cirrhosis, viral hepatitis and other liver diseases;
  3. Patients with serious heart, lung, kidney diseases and patients with cancer;
  4. Pregnant and nursing women;
  5. Other conditions that may affect the results of the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group

Participations in this group are required to follow a healthy vegetarian diet (avoid meat, poultry, fish, dairy) during the 24-weeks trail.

Daily energy intake = BMR(basal metabolic rate) × 1.25-500kcal;BMR = 370 + 21.6 × Lean body mass(kg) Requirements of energy supply ratio: protein 15%-20%; fat 20%-25%; carbohydrate 50%-60%.

Dietary guidance will be given to participants through monthly face-to-face interviews and biweekly telephone calls to change their dietary structure and energy intake.
Active Comparator: Control group

Participations in this group are required to follow a healthy omnivorous diet (No restriction on food sources) during the 24-weeks trail.

Daily energy intake = BMR × 1.25-500kcal;BMR = 370 + 21.6 × Lean body mass(kg) Requirements of energy supply ratio: protein 15%-20%; fat 20%-25%; carbohydrate 50%-60%.

Dietary guidance will be given to participants through monthly face-to-face interviews and biweekly telephone calls to change their dietary structure and energy intake.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The primary outcome was the weight of fat mass after 24 weeks intervention.
Time Frame: 24 weeks
Weight loss, especially the reduction of body fat mass, is the most important treatment for the prevention and treatment of MAFLD and its complicationsIn our study, we will measure weight of fat mass using a body composition analyzer (Biospace Inbody 720, Korea) at the baseline and after 24-week intervention. The difference in the weight of fat mass after intervention between the two groups is the primary outcome.
24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Results of B-ultrasonic examination and Fibroscan examination
Time Frame: 24 weeks
Imaging examination results are an important basis for the clinical diagnosis of NAFLD, which can show the degree of hepatic steatosis and hepatic fibrosis. Imaging findings of MAFLD will be measured and compared at the baseline and end of our study.
24 weeks
The changes of serum alanine aminotransferase (ALT) at week 24 intervention from the baseline
Time Frame: 24 weeks
Hepatic steatosis is often accompanied by changes in hepatic enzymes.
24 weeks
The changes of serum aspartate aminotransferase (AST) at week 24 intervention from the baseline
Time Frame: 24 weeks
Hepatic steatosis is often accompanied by changes in hepatic enzymes.
24 weeks
24-week weight change
Time Frame: 24 weeks
The 24-week intervention is expected to bring weight loss. We will compare the weight loss between the two groups
24 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Results of compliance survey will be collected every month.
Time Frame: 24 weeks
We have designed a compliance scale to evaluate the compliance , which may be important to advise the nutritionists and doctors about the prevention and treatment of MAFLD.
24 weeks
The difference of serum superoxide dismutase (SOD) level between two groups after 24-week intervention
Time Frame: 24 weeks
Cause vegetarian diet may contain more phytochemicals and less saturated fat and cholesterol due to the plant-based nature of the diet, resulting in better metabolic status and milder metabolic burden,we have presumed that the serum SOD level be different between two groups at the end of study.
24 weeks
The difference of metabolites of Intestinal flora between two groups after 24-week intervention.
Time Frame: 24 weeks
The fecal samples before and after the intervention to examine the effect of vegetarian diets on gut microbiota metabolites.
24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Xiuhua Shen, Professor, Xinhua Hospital Afflicated to Shanghai Jiaotong University of Medicin

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2022

Primary Completion (Estimated)

May 1, 2024

Study Completion (Estimated)

May 1, 2024

Study Registration Dates

First Submitted

May 23, 2022

First Submitted That Met QC Criteria

July 1, 2022

First Posted (Actual)

July 5, 2022

Study Record Updates

Last Update Posted (Actual)

May 14, 2024

Last Update Submitted That Met QC Criteria

May 13, 2024

Last Verified

November 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Liver Diseases

Clinical Trials on dietary intervention

Subscribe